ExonHit gets Innovative Company status from French innovation agency OSEO

14 Apr 2010 | News
French innovation-focused mutual funds can make tax-efficient equity investments in ExonHit Therapeutics for renewable 3-year periods.


French innovation-focused mutual funds can make tax-efficient equity investments in ExonHit Therapeutics for renewable 3-year periods.

ExonHit Therapeutics has announced that it has obtained the Innovative Company accreditation from OSEO, the French state innovation agency. This means that French innovation-focused mutual funds can make tax-efficient equity investments in ExonHit Therapeutics for renewable 3-year periods.

“We are delighted to have received this OSEO accreditation, which emphasises our particularly innovative strategy in genomic profiling, which we apply both in therapeutics and in diagnostics,” said Loïc Maurel, President of ExonHit.

“We are continuing our investment and research efforts with a view to offering personalised medical solutions in Alzheimer’s disease and cancer.”

Never miss an update from Science|Business:   Newsletter sign-up